Propranolol treatment of infantile hemangiomas: anticipatory guidance for parents and caretakers. Pediatr Dermatol 2013;30(1):155-9
Date
01/16/2013Pubmed ID
23316721Pubmed Central ID
PMC4786439DOI
10.1111/pde.12022Scopus ID
2-s2.0-84872359114 (requires institutional sign-in at Scopus site) 31 CitationsAbstract
Infantile hemangiomas (IH) are benign tumors of endothelial-like cells. Occurring in 4.5% of children, they are the most common tumor of childhood. The great majority of patients with IH will not need treatment, but 10% require systemic treatment. Many treatments have been described for the treatment of IH, but the Food and Drug Administration has not approved any. Over the last decade, numerous reports of successful treatment of IH with propranolol have been published. Despite its widespread use, little is known regarding the proper dosing, safety monitoring, and during of treatment or long-term outcomes for propranolol treatment of IH. Given its potential side effects, detailed education regarding proper administration of the medication as well as warning signs to watch for is necessary for parents and caretakers. Herein, we provide a parental handout that practitioners can individually tailor for use in their clinics when educating parents and caretakers about the use of propranolol for IH. Updates will also need to be made as more is learned regarding the optimal dosing and safety monitoring when using propranolol for this indication.
Author List
Martin K, Blei F, Chamlin SL, Chiu YE, Frieden IJ, Frommelt PC, Garzon MC, Kwon EK, MacLellan-Tobert S, Mancini AJ, Seefeldt M, Sidbury R, Siegel DH, Drolet BA, Boucek RJAuthors
Yvonne E. Chiu MD Vice Chair, Professor in the Dermatology department at Medical College of WisconsinPeter C. Frommelt MD Adjunct Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
CaregiversDose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Guidelines as Topic
Hemangioma, Capillary
Humans
Infant
Infant, Newborn
Male
Neoplastic Syndromes, Hereditary
Parents
Propranolol
Risk Assessment
Skin Neoplasms
Treatment Outcome
